GO:0009217 purine deoxyribonucleoside triphosphate catabolic process: Nucleotide Pool Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009217 describes the biochemical breakdown of purine deoxyribonucleoside triphosphates (dNTPs) such as dATP and dGTP, a process critical for maintaining balanced intracellular dNTP pools.
• Imbalances in purine dNTP catabolism are linked to resistance to nucleoside analog drugs like cladribine, used in hairy cell leukemia and multiple sclerosis [1,3].
• Key enzymes include purine nucleoside phosphorylase (PNP) and adenosine deaminase (ADA); deficiencies cause severe immunodeficiency due to dNTP toxicity.
• The catabolic process counteracts hydroxyurea-induced dNTP pool depletion, highlighting its role in DNA synthesis regulation.
• Understanding this pathway informs development of antiviral and anticancer agents, including islatravir-triphosphate with extended half-life.
• CRISPR-based models (knockout, point mutation, knock-in) enable precise dissection of catabolic enzyme function in disease contexts [1,5].
Description
Purine deoxyribonucleoside triphosphate catabolic process (GO:0009217) encompasses the chemical reactions that degrade purine dNTPs, including dATP and dGTP, into their constituent bases and sugars. This process is essential for maintaining the delicate balance of intracellular dNTP pools required for faithful DNA replication and repair. Dysregulation of this catabolic pathway can lead to altered sensitivity to nucleoside analog therapeutics, as seen in cladribine-resistant leukemias. Moreover, inherited defects in purine catabolic enzymes such as adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) cause severe immunodeficiencies due to accumulation of toxic deoxyribonucleosides. Researchers study GO:0009217 to understand nucleotide homeostasis, drug resistance mechanisms, and to develop targeted therapies for cancers and immune disorders [3,4].
purine deoxyribonucleoside triphosphate catabolic process At A Glance
| GO ID | GO:0009217 |
|---|---|
| GO term | purine deoxyribonucleoside triphosphate catabolic process |
| Ontology | biological_process |
| Synonym | purine deoxyribonucleoside triphosphate breakdown; purine deoxyribonucleoside triphosphate catabolism; purine deoxyribonucleoside triphosphate degradation |
| Major function | Breakdown of purine dNTPs to regulate intracellular nucleotide pools and prevent toxicity [5,6] |
| Related enzymes | Purine nucleoside phosphorylase (PNP), adenosine deaminase (ADA), and other nucleotidases |
| Disease relevance | Immunodeficiency, leukemia drug resistance, and antiviral/anticancer drug metabolism [1,3,5] |
| Research methods | CRISPR knockout, metabolic labeling, dNTP pool quantification, and enzymatic assays |
What Is GO:0009217?
GO:0009217 is defined as the chemical reactions and pathways resulting in the breakdown of a purine deoxyribonucleoside triphosphate, a compound consisting of a purine base linked to a deoxyribose sugar esterified with triphosphate on the sugar. In simpler terms, it is the biological process that dismantles the building blocks of DNA (specifically the purine ones, dATP and dGTP) when they are no longer needed or are present in excess.
Why Is purine deoxyribonucleoside triphosphate catabolic process Important in Cell Biology?
GO:0009217 is crucial because it governs the catabolism of purine dNTPs, directly impacting DNA synthesis, repair, and cell proliferation. Proper regulation prevents the accumulation of toxic deoxyribonucleosides that can cause immunodeficiency, as observed in ADA and PNP deficiencies. Additionally, the pathway influences the efficacy of nucleoside analog drugs like cladribine, where resistance often arises from altered catabolism. Understanding this process aids in designing better therapies for cancers and viral infections, as evidenced by studies on islatravir-triphosphate half-life.
• Maintains balanced dNTP pools to ensure genomic stability during DNA replication.
• Prevents toxicity from excess deoxyribonucleosides, which can cause lymphocyte apoptosis in immunodeficiency disorders.
• Modulates sensitivity to nucleoside analog chemotherapeutics such as cladribine.
• Influences the pharmacokinetics and efficacy of antiviral drugs like islatravir.
• Provides targets for immunosuppressive and anticancer drug development.
• Plays a role in counteracting hydroxyurea-induced dNTP depletion.
• Involved in the metabolism of unnatural nucleosides used in chemical biology.
• Relevant to bacteriophage Z genome biosynthesis, where modified nucleotides are catabolized.
• Impacts AMPK activation by cordycepin, linking nucleotide catabolism to energy sensing.
• Serves as a model for studying enzyme evolution and substrate specificity.
What Happens During purine deoxyribonucleoside triphosphate catabolic process?
Dephosphorylation of Purine dNTPs
In simple terms: The triphosphate groups are removed step by step from the DNA building blocks.
The catabolic process begins with the sequential removal of phosphate groups from purine dNTPs (dATP, dGTP) by nucleotidases and phosphatases, yielding deoxyribonucleoside diphosphates and monophosphates. This step is critical for reducing the pool of available dNTPs for DNA synthesis. Studies on hydroxyurea-treated cells show that purine deoxyribonucleosides can counteract dNTP pool depletion, indicating that dephosphorylation is a regulated entry point into catabolism.
Phosphorolysis by Purine Nucleoside Phosphorylase (PNP)
In simple terms: The sugar and base are split apart by a specific enzyme.
Purine nucleoside phosphorylase (PNP) catalyzes the reversible phosphorolysis of purine deoxyribonucleosides (e.g., deoxyinosine, deoxyguanosine) to their respective bases (hypoxanthine, guanine) and deoxyribose-1-phosphate. This step is a central node in purine catabolism. Deficiencies in PNP lead to accumulation of deoxyguanosine and dGTP, causing T-cell immunodeficiency. The enzyme's specificity and regulation are key to maintaining nucleotide homeostasis.
Deamination by Adenosine Deaminase (ADA)
In simple terms: An amino group is removed from adenosine or deoxyadenosine, converting it to inosine or deoxyinosine.
Adenosine deaminase (ADA) irreversibly deaminates adenosine and deoxyadenosine to inosine and deoxyinosine, respectively. This reaction is essential for purine catabolism, and ADA deficiency results in severe combined immunodeficiency (SCID) due to toxic accumulation of dATP, which inhibits ribonucleotide reductase and DNA synthesis. The deamination step feeds into the PNP pathway for further breakdown.
Further Degradation to Uric Acid
In simple terms: The purine ring is eventually broken down to uric acid for excretion.
Following deamination and phosphorolysis, the purine bases (hypoxanthine, guanine) are further oxidized by xanthine oxidase to uric acid in humans. This terminal step completes the catabolic process. While GO:0009217 focuses on dNTP breakdown, the resulting bases enter this common purine catabolic pathway. The overall process ensures that excess purine dNTPs are eliminated, preventing toxicity and maintaining nucleotide balance [5,6].
Regulation of dNTP Pools by Catabolism
In simple terms: The breakdown process is tuned to keep dNTP levels just right for DNA copying.
The catabolic process is tightly regulated to match dNTP supply with demand during cell cycle. Hydroxyurea, which inhibits ribonucleotide reductase and depletes dNTP pools, can be counteracted by exogenous purine deoxyribonucleosides, suggesting that catabolic enzymes modulate pool size. Additionally, the half-life of islatravir-triphosphate, a modified dNTP analog, is influenced by catabolic stability, highlighting the interplay between synthesis and degradation.
Key Genes Involved in GO:0009217 purine deoxyribonucleoside triphosphate catabolic process
The following genes encode enzymes and regulators directly involved in purine deoxyribonucleoside triphosphate catabolism, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADA | Deaminates adenosine/deoxyadenosine | ADA deficiency causes SCID; target for gene therapy |
| PNP | Phosphorolyzes purine deoxyribonucleosides | PNP deficiency leads to T-cell immunodeficiency |
| DCK | Phosphorylates deoxycytidine and analogs | Activates cladribine; resistance linked to DCK deficiency |
| NT5C2 | Dephosphorylates nucleoside monophosphates | Mutations cause thiopurine resistance in leukemia |
| RRM1 | Ribonucleotide reductase subunit | Regulates dNTP synthesis; target of hydroxyurea |
| RRM2 | Ribonucleotide reductase subunit | Influences dNTP pools and drug sensitivity |
| XDH | Xanthine dehydrogenase/oxidase | Terminal purine catabolism to uric acid |
| HPRT1 | Hypoxanthine phosphoribosyltransferase | Salvage enzyme; deficiency causes Lesch-Nyhan |
| APRT | Adenine phosphoribosyltransferase | Salvage of adenine; deficiency causes kidney stones |
| ADAL | Adenosine deaminase-like | May contribute to purine catabolism |
| CMPK1 | UMP-CMP kinase | Phosphorylates nucleoside monophosphates in catabolism |
| NME1 | Nucleoside diphosphate kinase | Maintains dNTP balance |
| ENT1 | Equilibrative nucleoside transporter | Uptake of nucleosides for catabolism |
| CNT2 | Concentrative nucleoside transporter | Transport of purine nucleosides |
| ITPA | Inosine triphosphatase | Hydrolyzes ITP to prevent incorporation |
| SAMHD1 | dNTP triphosphohydrolase | Degrades dNTPs to regulate pools |
| TREX1 | Exonuclease | Links dNTP catabolism to DNA damage responses |
How Is purine deoxyribonucleoside triphosphate catabolic process Regulated?
The purine deoxyribonucleoside triphosphate catabolic process is regulated at multiple levels. Enzyme expression and activity of ADA and PNP are modulated during lymphocyte development, with deficiencies causing immunodeficiency. dNTP pool size is balanced by feedback inhibition of ribonucleotide reductase and by catabolic enzymes like SAMHD1, which hydrolyzes dNTPs. Additionally, AMPK activation by cordycepin, a purine analog, links nucleotide catabolism to energy sensing pathways. Hydroxyurea treatment alters dNTP pools, and purine deoxyribonucleosides can counteract these effects, indicating cross-talk between synthesis and catabolism.
purine deoxyribonucleoside triphosphate catabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADA | Severe combined immunodeficiency (SCID) | ADA knockout mice; patient-derived iPSCs |
| PNP | T-cell immunodeficiency | PNP knockout mice; T-cell lines |
| DCK | Cladribine resistance in leukemia | DCK knockout leukemia cell lines |
| NT5C2 | Thiopurine resistance in leukemia | NT5C2 mutant knock-in cells |
| SAMHD1 | HIV restriction and dNTP regulation | SAMHD1 knockout macrophages |
Immunodeficiency Disorders
Deficiencies in ADA and PNP cause severe combined immunodeficiency (SCID) and T-cell immunodeficiency, respectively, due to accumulation of toxic deoxyribonucleosides and dNTPs that impair lymphocyte proliferation. These conditions highlight the critical role of purine dNTP catabolism in immune cell homeostasis.
Cancer Drug Resistance
Resistance to cladribine, a purine nucleoside analog used in hairy cell leukemia, is often associated with altered expression of enzymes involved in purine dNTP catabolism, such as DCK and NT5C2. Understanding these mechanisms can guide combination therapies.
Antiviral Therapy
The half-life of islatravir-triphosphate, an investigational anti-HIV drug, is influenced by intracellular catabolism, supporting extended dosing intervals. Modulating catabolic enzymes could optimize antiviral efficacy.
Metabolic and Neurological Disorders
Defects in purine salvage and catabolism, such as HPRT1 deficiency, cause Lesch-Nyhan syndrome, characterized by neurological dysfunction. This underscores the importance of nucleotide balance in the nervous system.
From purine deoxyribonucleoside triphosphate catabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ADA loss cause dATP accumulation and toxicity? | ADA knockout cell line (e.g., HEK293) |
| How does PNP deficiency affect T-cell survival? | PNP knockout Jurkat cells |
| Does DCK mutation confer cladribine resistance? | DCK point mutation knock-in in leukemia cells |
| Can SAMHD1 hydrolysis be tracked? | SAMHD1 tagged knock-in for live imaging |
| Does NT5C2 overexpression alter drug sensitivity? | NT5C2 overexpression in cancer cell lines |
| What is the effect of purine deoxyribonucleosides on dNTP pools? | Hydroxyurea-treated cells with nucleoside supplementation |
How to Study the purine deoxyribonucleoside triphosphate catabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| HPLC | Intracellular dNTP concentrations | Assessing pool size after gene knockout |
| LC-MS/MS | dNTP and nucleoside levels | Quantifying drug metabolite half-life |
| Enzyme activity assay | ADA or PNP catalytic rate | Characterizing patient mutations |
| CRISPR screen | Gene essentiality or drug sensitivity | Identifying resistance genes |
| Western blot | Protein expression of catabolic enzymes | Validating knockout or overexpression |
| qRT-PCR | mRNA levels of genes like ADA, PNP | Assessing transcriptional regulation |
| Flow cytometry | Cell viability and apoptosis | Measuring toxicity of dNTP imbalance |
| Isotope tracing | Metabolic flux through catabolism | Dynamic measurement of dNTP turnover |
dNTP Pool Quantification
High-performance liquid chromatography (HPLC) or mass spectrometry-based methods are used to measure intracellular dNTP levels, providing direct readouts of catabolic activity. These techniques are essential for studying how genetic perturbations affect purine dNTP catabolism.
Enzymatic Activity Assays
In vitro assays using purified enzymes (e.g., ADA, PNP) or cell lysates measure deamination or phosphorolysis rates, allowing kinetic characterization of catabolic enzymes. Such assays are used to assess the impact of mutations or inhibitors.
CRISPR-Based Genetic Screens
Pooled CRISPR knockout libraries can identify genes that modulate sensitivity to nucleoside analogs, revealing novel regulators of purine dNTP catabolism. This approach is powerful for drug resistance studies.
Metabolic Labeling and Tracing
Stable isotope labeling with 13C/15N-purine nucleosides followed by mass spectrometry tracks the flux through catabolic pathways, offering dynamic insights into dNTP turnover.
How CRISPR Can Be Used to Study GO:0009217 purine deoxyribonucleoside triphosphate catabolic process
Knockout
CRISPR knockout of genes such as ADA or PNP in cell lines (e.g., HEK293, Jurkat) recapitulates immunodeficiency phenotypes, allowing study of dNTP accumulation and toxicity. Knockout of DCK confers resistance to cladribine, validating its role in drug activation.
Point Mutation
Introducing patient-specific point mutations (e.g., in ADA or NT5C2) via CRISPR base editing or HDR enables precise modeling of enzyme deficiencies and drug resistance without complete gene loss [1,5].
Knock-in
Knock-in of tagged versions of catabolic enzymes (e.g., SAMHD1-FLAG) allows live-cell imaging and proteomic analysis of their localization and interactions, providing insights into regulation.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of genes like NT5C2 or SAMHD1 can test their sufficiency in altering dNTP pools and drug sensitivity, complementing loss-of-function studies [1,4].
How EDITGENE Supports purine deoxyribonucleoside triphosphate catabolic process Research
Researchers studying purine deoxyribonucleoside triphosphate catabolic process-related genes often need to determine whether a candidate gene is causally involved in nucleotide pool regulation, drug resistance, or immune cell survival. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of genes in this pathway.
Contact EDITGENE today to design your custom CRISPR model for purine deoxyribonucleoside triphosphate catabolic process research.
Frequently Asked Questions About purine deoxyribonucleoside triphosphate catabolic process
What is purine deoxyribonucleoside triphosphate catabolic process?
It is the biological process (GO:0009217) that breaks down purine dNTPs like dATP and dGTP into their bases and sugars, helping to regulate DNA building block pools.
What genes are involved in purine deoxyribonucleoside triphosphate catabolic process?
Key genes include ADA, PNP, DCK, NT5C2, SAMHD1, and XDH, which encode enzymes that deaminate, phosphorolyze, or hydrolyze purine dNTPs [1,4,5].
Why is purine dNTP catabolism important for cancer therapy?
It influences sensitivity to nucleoside analogs like cladribine; altered catabolism can cause drug resistance in leukemia.
How does ADA deficiency relate to purine dNTP catabolism?
ADA deficiency blocks deamination of deoxyadenosine, leading to dATP accumulation and severe combined immunodeficiency.
What methods are used to study purine dNTP catabolism?
Common methods include HPLC for dNTP quantification, enzyme activity assays, CRISPR screens, and metabolic labeling [4,6].
Can CRISPR be used to model purine dNTP catabolic defects?
Yes, CRISPR knockout or point mutation of genes like ADA or PNP in cell lines recapitulates disease phenotypes [1,5].
What is the role of SAMHD1 in dNTP catabolism?
SAMHD1 is a dNTP triphosphohydrolase that degrades dNTPs, regulating intracellular pools and restricting HIV replication.
How does hydroxyurea affect purine dNTP pools?
Hydroxyurea inhibits ribonucleotide reductase, depleting dNTP pools; purine deoxyribonucleosides can counteract this effect.
What diseases are linked to defects in purine catabolism?
ADA and PNP deficiencies cause immunodeficiencies; HPRT1 deficiency causes Lesch-Nyhan syndrome; altered catabolism contributes to drug resistance [1,5].
What cell models are available for studying GO:0009217?
EDITGENE provides knockout, point mutation, knock-in, and overexpression cell models for genes in this pathway [1,4,5].
Conclusion
GO:0009217 purine deoxyribonucleoside triphosphate catabolic process is a fundamental pathway that maintains dNTP homeostasis and prevents toxic nucleotide accumulation. Its dysregulation underlies immunodeficiencies and drug resistance in cancer, making it a critical area for therapeutic research [1,5]. Advances in CRISPR-based modeling and analytical methods continue to unravel the complexities of this process, offering new opportunities for drug development and personalized medicine [4,6].
References
- 1. Lotfi K et al.. 2003. Pharmacological basis for cladribine resistance.. Leuk Lymphoma 44(10):1705-12 PMID: 14692522
- 2. Chen HY et al.. 2023. Progress on Z genome biosynthetic pathway of bacteriophage.. Yi Chuan 45(10):887-903 PMID: 37872112
- 3. Liliemark J. 1997. The clinical pharmacokinetics of cladribine.. Clin Pharmacokinet 32(2):120-31 PMID: 9068927
- 4. Zang X et al.. 2024. Intracellular islatravir-triphosphate half-life supports extended dosing intervals.. Antimicrob Agents Chemother 68(9):e0045824 PMID: 39105584
- 5. Carson DA et al.. 1978. Deoxyribonucleoside toxicity in adenosine deaminase and purine nucleoside phosphorylase deficiency: implications for the development of new immunosuppressive agents.. Ciba Found Symp PMID: 115660
- 6. Lagergren J et al.. 1987. Purine deoxyribonucleosides counteract effects of hydroxyurea on deoxyribonucleoside triphosphate pools and DNA synthesis.. Biochem Pharmacol 36(18):2985-91 PMID: 3498491
- 7. Hawley SA et al.. 2020. Mechanism of Activation of AMPK by Cordycepin.. Cell Chem Biol 27(2):214-222.e4 PMID: 31991096
- 8. Wu Y et al.. 2002. Enzymatic phosphorylation of unnatural nucleosides.. J Am Chem Soc 124(49):14626-30 PMID: 12465973
